117 related articles for article (PubMed ID: 38440890)
1. MECOM: a bioinformatics and experimentally identified marker for the diagnosis and prognosis of lung adenocarcinoma.
Li A; Li M; Wang J; Zhou J; Yang T; Fan M; Zhang K; Gao H; Ren H; Chen M
Biomark Med; 2024 Jan; 18(2):79-91. PubMed ID: 38440890
[TBL] [Abstract][Full Text] [Related]
2. MECOM/PRDM3 and PRDM16 Serve as Prognostic-Related Biomarkers and Are Correlated With Immune Cell Infiltration in Lung Adenocarcinoma.
Li M; Ren H; Zhang Y; Liu N; Fan M; Wang K; Yang T; Chen M; Shi P
Front Oncol; 2022; 12():772686. PubMed ID: 35174083
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
[TBL] [Abstract][Full Text] [Related]
4. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
5. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
6. A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma.
Li X; Gu Y; Hu B; Shao MM; Li H
Thorac Cancer; 2024 Jun; 15(16):1312-1319. PubMed ID: 38682829
[TBL] [Abstract][Full Text] [Related]
7. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
Zhou J; Wang X; Li Z; Jiang R
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
[TBL] [Abstract][Full Text] [Related]
8. Identification of
Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H
Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of serum DJ-1 in lung adenocarcinoma.
Wang L; Wei L; Miao S; Zhang W
PeerJ; 2024; 12():e16845. PubMed ID: 38304191
[TBL] [Abstract][Full Text] [Related]
10. Microarray expression profile of microRNAs in lung adenocarcinoma patients with the Cancer Genome Atlas and its clinical validation.
Chen G; Xing Y; Peng X; Miao L; Zhao M; Zhou H; Xiao Y
J BUON; 2020; 25(2):821-827. PubMed ID: 32521873
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Four-Gene Signature Associated with the Prognosis Prediction of Lung Adenocarcinoma Based on Integrated Bioinformatics Analysis.
Wu Y; Yang L; Zhang L; Zheng X; Xu H; Wang K; Weng X
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205284
[TBL] [Abstract][Full Text] [Related]
12. ADAR1 is a prognostic biomarker and is correlated with immune infiltration in lung adenocarcinoma.
Yang W; Chen K; Yu Q; Liao R; He H; Peng Y; Yang Z; Zhang X
Cancer Med; 2023 Jul; 12(13):14820-14832. PubMed ID: 37162299
[TBL] [Abstract][Full Text] [Related]
13. Tubulin Alpha-1b as a Potential Biomarker for Lung Adenocarcinoma Diagnosis and Prognosis.
Pang XL; Du HF; Nie F; Yang XG; Xu Y
Technol Cancer Res Treat; 2023; 22():15330338231178391. PubMed ID: 37489256
[No Abstract] [Full Text] [Related]
14. Identification of Small Nucleolar RNA SNORD60 as a Potential Biomarker and Its Clinical Significance in Lung Adenocarcinoma.
Zhou H; Yao Y; Li Y; Guo N; Zhang H; Wang Z; Chen Y; Dai G
Biomed Res Int; 2022; 2022():5501171. PubMed ID: 35711521
[TBL] [Abstract][Full Text] [Related]
15. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
17. Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma.
Li J; Li J; Hao H; Lu F; Wang J; Ma M; Jia B; Zhuo M; Wang J; Chi Y; Zhai X; Wang Y; Wu M; An T; Zhao J; Yang F; Wang Z
BMC Cancer; 2023 Jan; 23(1):110. PubMed ID: 36721112
[TBL] [Abstract][Full Text] [Related]
18. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
19. A two-circular RNA signature as a noninvasive diagnostic biomarker for lung adenocarcinoma.
Liu XX; Yang YE; Liu X; Zhang MY; Li R; Yin YH; Qu YQ
J Transl Med; 2019 Feb; 17(1):50. PubMed ID: 30777071
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]